DE122012000038I1 - HIV hemmende pyrimidine derivaten. - Google Patents

HIV hemmende pyrimidine derivaten.

Info

Publication number: DE122012000038I1
Authority: DE; Germany
Prior art keywords: hiv; pyrimidine derivatives; inhibiting pyrimidine; inhibiting; derivatives
Prior art date: 2001-08-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

DE201212000038

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceutica NV

Original Assignee

Janssen Pharmaceutica NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-13

Filing date

2012-05-25

Publication date

2012-09-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26076978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122012000038(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

US case filed in Delaware District Court litigation https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A20-cv-00189 Source: District Court Jurisdiction: Delaware District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.

2012-05-25 Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV

2012-09-20 Publication of DE122012000038I1 publication Critical patent/DE122012000038I1/de

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DE201212000038 2001-08-13 2012-05-25 HIV hemmende pyrimidine derivaten. Pending DE122012000038I1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP01203090		2001-08-13
EP02077748		2002-06-10
EP02764839A EP1419152B1 (de)	2001-08-13	2002-08-09	Hiv hemmende pyrimidine derivaten
PCT/EP2002/008953 WO2003016306A1 (en)	2001-08-13	2002-08-09	Hiv inhibiting pyrimidines derivatives

Publications (1)

Publication Number	Publication Date
DE122012000038I1 true DE122012000038I1 (de)	2012-09-20

Family

ID=26076978

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE201212000038 Pending DE122012000038I1 (de)	2001-08-13	2012-05-25	HIV hemmende pyrimidine derivaten.

Country Status (37)

Country	Link
US (8)	US7125879B2 (de)
EP (3)	EP2298761B1 (de)
JP (4)	JP2005507380A (de)
KR (2)	KR100817453B1 (de)
CN (2)	CN100509801C (de)
AP (1)	AP1610A (de)
AR (1)	AR036387A1 (de)
AT (1)	ATE517891T1 (de)
AU (1)	AU2002329238C1 (de)
BE (3)	BE2012C020I2 (de)
BR (3)	BR122015023612B8 (de)
CA (1)	CA2452217C (de)
CY (4)	CY1112331T1 (de)
DE (1)	DE122012000038I1 (de)
DK (2)	DK3808743T3 (de)
EA (1)	EA006656B1 (de)
EG (1)	EG24684A (de)
ES (3)	ES2368996T3 (de)
FR (3)	FR12C0035I2 (de)
HR (3)	HRP20040096B1 (de)
HU (5)	HU231274B1 (de)
IL (2)	IL160328A0 (de)
JO (1)	JO3429B1 (de)
LT (3)	LT3808743T (de)
LU (2)	LU92001I2 (de)
MX (1)	MXPA04001401A (de)
MY (1)	MY189572A (de)
NO (3)	NO327639B1 (de)
NZ (1)	NZ530951A (de)
OA (1)	OA12652A (de)
PA (1)	PA8552901A1 (de)
PL (2)	PL216398B1 (de)
PT (1)	PT1419152E (de)
SI (2)	SI3808743T1 (de)
UA (1)	UA78221C2 (de)
WO (1)	WO2003016306A1 (de)
ZA (1)	ZA200401159B (de)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) *	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) *	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en)	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
ES2347544T3 (es)	2002-03-13	2010-11-02	Janssen Pharmaceutica Nv	Inhibidores de histona-desacetilasas.
AR039540A1 (es)	2002-05-13	2005-02-23	Tibotec Pharm Ltd	Compuestos microbicidas con contenido de pirimidina o triazina
JP2006514989A (ja)	2002-07-29	2006-05-18	ライジェルファーマシューティカルズ	２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
HRP20050104B1 (hr) *	2002-08-09	2014-02-14	Janssen Pharmaceutica N.V.	Postupci za pripremu 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
PL377795A1 (pl) *	2002-11-28	2006-02-20	Schering Aktiengesellschaft	Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych
AP2005003365A0 (en) *	2003-02-07	2005-09-30	Janssen Pharmaceutica Nv	Hiv inhibiting 1, 2, 4-triazines.
CN102151270A (zh) *	2003-02-07	2011-08-17	詹森药业有限公司	预防hiv感染的嘧啶衍生物
CL2004000303A1 (es)	2003-02-20	2005-04-08	Tibotec Pharm Ltd	Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
US20060172010A1 (en)	2003-07-17	2006-08-03	Gael Lamoureux	Process for preparing particles containing an antiviral
AU2004265288A1 (en)	2003-07-30	2005-02-24	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
SG145749A1 (en) *	2003-08-15	2008-09-29	Novartis Ag	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
TWI365744B (en) *	2003-09-03	2012-06-11	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
BRPI0414791A (pt) *	2003-09-25	2006-11-21	Janssen Pharmaceutica Nv	derivados de purina inibidores da replicação do hiv
CA2567574C (en)	2004-04-08	2013-01-08	Targegen, Inc.	Benzotriazine inhibitors of kinases
PL1781639T3 (pl)	2004-07-28	2012-07-31	Janssen Pharmaceutica Nv	Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
JP5031564B2 (ja)	2004-08-10	2012-09-19	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｈｉｖ抑制１，２，４−トリアジン−６−オン誘導体
PT2135608E (pt)	2004-08-25	2012-01-13	Ardea Biosciences Inc	S-triazolil-alfa-mercaptoacetanilidas como inibidores de transcritase inversa de vih
WO2007050087A1 (en)	2004-08-25	2007-05-03	Ardea Biosciences, Inc.	N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
JP4912309B2 (ja) *	2004-09-02	2012-04-11	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの塩酸塩
CA2577288C (en) *	2004-09-02	2010-11-30	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AU2005279157B2 (en) *	2004-09-02	2011-07-14	Janssen Pharmaceutica N.V.	Fumarate of 4-[[4-[[4- (2-cyanoethenyl) -2,6-dimethylphenyl]amino)-2-pyrimidinyl)amino]benzonitrile
CN101068597B (zh) *	2004-09-02	2012-04-18	詹森药业有限公司	4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
MX2007002594A (es) *	2004-09-02	2007-04-25	Janssen Pharmaceutica Nv	Fumarato de 4-((4-((4- (2-cianoetenil)-2, 6-dimetilfenil) amino)-2-pirimidinil) amino) benzonitrilo.
US7767677B2 (en)	2004-09-20	2010-08-03	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1814551A2 (de)	2004-09-20	2007-08-08	Xenon Pharmaceuticals Inc.	Pyridazin-derivate zur verhinderung menschlicher stearoyl-coa-desaturase
US8071603B2 (en)	2004-09-20	2011-12-06	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580857A1 (en)	2004-09-20	2006-09-28	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286793A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
CA2580762A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as therapeutic agents
AU2005286728A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
RU2410379C2 (ru)	2004-09-30	2011-01-27	Тиботек Фармасьютикалз Лтд.	5-замещенные пиримидины, ингибирующие вич
WO2006035067A2 (en)	2004-09-30	2006-04-06	Tibotec Pharmaceuticals Ltd.	Hiv inhibiting 5-heterocyclyl pyrimidines
CA2573976C (en) *	2004-09-30	2014-04-29	Tibotec Pharmaceuticals Ltd.	Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
EP1814878B1 (de)	2004-11-24	2012-01-04	Rigel Pharmaceuticals, Inc.	Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US7449458B2 (en)	2005-01-19	2008-11-11	Rigel Pharmaceuticals, Inc.	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2006106914A1 (ja)	2005-03-31	2006-10-12	Santen Pharmaceutical Co., Ltd.	ピリミジニルアルキルチオ基を有する新規環式化合物
TWI457136B (zh) *	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
ATE541848T1 (de)	2005-05-05	2012-02-15	Ardea Biosciences Inc	Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
CN101248051B (zh) *	2005-05-26	2013-07-17	泰博特克药品有限公司	制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法
MX2007015216A (es)	2005-06-03	2008-02-22	Xenon Pharmaceuticals Inc	Derivados de aminotiazol y sus usos como agentes terapeuticos.
NZ563454A (en)	2005-06-08	2011-03-31	Rigel Pharmaceuticals Inc	2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
AU2006309013B2 (en)	2005-11-01	2012-06-28	Impact Biomedicines, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
JP5247470B2 (ja)	2006-01-19	2013-07-24	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
AR059097A1 (es)	2006-01-20	2008-03-12	Tibotec Pharm Ltd	Tratamiento a largo plazo de la infeccion por vih
DK2004641T3 (da)	2006-03-30	2011-01-24	Tibotec Pharm Ltd	HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
MX2008012576A (es)	2006-03-30	2008-10-10	Tibotec Pharm Ltd	Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
AU2014200819B2 (en) *	2006-06-23	2016-05-26	Janssen Sciences Ireland Uc	Aqueous suspensions of TMC278
BRPI0713334B1 (pt) *	2006-06-23	2024-02-20	Janssen Sciences Ireland Uc	Uso de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrila para tratar ou prevenir infecção por HIV
AU2016219555B2 (en) *	2006-06-23	2017-08-10	Janssen Sciences Ireland Uc	Aqueous suspensions of TMC278
CA2668997C (en)	2006-11-09	2012-10-09	Ardea Biosciences, Inc.	4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
GEP20125691B (en)	2006-12-08	2012-11-26	Irm Llc	Compounds and compositions as protein kinase inhibitors
RU2469032C2 (ru) *	2006-12-13	2012-12-10	Ф.Хоффманн-Ля Рош Аг	Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
BRPI0720858B8 (pt)	2006-12-29	2021-05-25	Janssen R & D Ireland	pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
ES2618057T3 (es)	2006-12-29	2017-06-20	Janssen Sciences Ireland Uc	Pirimidinas 5,6-sustituidas inhibidoras del VIH
WO2008094992A2 (en)	2007-01-31	2008-08-07	Vertex Pharmaceuticals Incorporated	2-aminopyridine derivatives useful as kinase inhibitors
TWI494133B (zh) *	2007-03-14	2015-08-01	Tibotec Pharm Ltd	重組用粉末
UA97834C2 (ru)	2007-04-18	2012-03-26	Пфайзер Продактс Инк.	Производные сульфониламида для лечения анормального роста клеток
AU2008257771B2 (en)	2007-05-30	2015-02-19	F. Hoffmann-La Roche Ag	Non-nucleoside reverse transcriptase inhibitors
KR101294731B1 (ko) *	2007-06-04	2013-08-16	삼성디스플레이 주식회사	어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
RU2498979C2 (ru) *	2007-07-12	2013-11-20	Тиботек Фармасьютикалз	Кристаллическая форма 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
CN101407476B (zh) *	2007-10-12	2012-07-18	中国人民解放军军事医学科学院毒物药物研究所	作为非核苷类hiv逆转录酶抑制剂的间二芳烃-多取代苯胺类化合物、其制备方法及用途
KR101291643B1 (ko)	2007-11-27	2013-08-01	아디아 바이오사이언스즈 인크.	신규한 화합물 및 조성물과 사용 방법
CA2709176C (en)	2007-12-14	2013-02-05	Ardea Biosciences, Inc.	Reverse transcriptase inhibitors
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
MX382352B (es)	2008-06-27	2025-03-13	Celgene Car Llc	Compuestos de heteroarilo y usos de los mismos.
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2328896B1 (de)	2008-07-23	2013-10-23	Vertex Pharmaceuticals Incorporated	Tricyclische pyrazolopyridine als kinaseinhibitoren
US8569337B2 (en)	2008-07-23	2013-10-29	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
AU2009274011B2 (en)	2008-07-23	2014-12-18	Vertex Pharmaceuticals Incorporated	Pyrazolopyridine kinase inhibitors
EP2313372B1 (de) *	2008-08-06	2013-04-10	Vertex Pharmaceuticals Incorporated	Aminopyridine als kinaseinhibitoren
EP2351739B1 (de) *	2008-10-09	2013-07-31	Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China	2-(4-substitutierte phenylamino) polysubstituierte pyridinverbindungen als hemmer der nichtnukleosidischen hiv-reverse-transkriptase, herstellungsverfahren und verwendung
CN101717364B (zh) *	2008-10-09	2014-08-13	中国人民解放军军事医学科学院毒物药物研究所	作为hiv逆转录酶抑制剂的吡啶类化合物及其制备方法和用途
EP2181991A1 (de)	2008-10-28	2010-05-05	LEK Pharmaceuticals D.D.	Neuartige Sunitinib-Salze
EP2186809A1 (de)	2008-11-13	2010-05-19	LEK Pharmaceuticals D.D.	Neue kristalline Form von Sunitinib-Malat
KR101726615B1 (ko)	2008-12-24	2017-04-13	얀센 사이언시즈 아일랜드 유씨	Ｈｉｖ 치료용 체내 임플란트 장치
ES2659725T3 (es)	2009-05-05	2018-03-19	Dana-Farber Cancer Institute, Inc.	Inhibidores de EGFR y procedimiento de tratamiento de trastornos
CN102459259A (zh)	2009-05-06	2012-05-16	沃泰克斯药物股份有限公司	吡唑并吡啶类
JP2013518114A (ja)	2010-01-27	2013-05-20	バーテックスファーマシューティカルズインコーポレイテッド	ピラゾロピリミジンキナーゼ阻害剤
CA2787315A1 (en)	2010-01-27	2011-08-04	Vertex Pharmaceuticals Incorporated	Pyrazolopyridine kinase inhibitors
EP2550272A1 (de)	2010-01-27	2013-01-30	Vertex Pharmaceuticals Incorporated	Pyrazolopyrazinkinasehemmer
KR20170078868A (ko)	2010-01-27	2017-07-07	비이브 헬쓰케어 컴퍼니	항바이러스 치료
WO2011103457A1 (en)	2010-02-18	2011-08-25	Concert Pharmaceuticals Inc.	Pyrimidine derivatives
US8367315B2 (en) *	2010-03-05	2013-02-05	Adan Rios	Inactivation of reverse transcriptases by azido-diarylpyrimidines
NZ607845A (en)	2010-08-10	2015-03-27	Celgene Avilomics Res Inc	Besylate salt of a btk inhibitor
CA2815858C (en)	2010-11-01	2018-10-16	Celgene Avilomics Research, Inc.	Heterocyclic compounds and uses thereof
US9238629B2 (en)	2010-11-01	2016-01-19	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
CA2816957A1 (en)	2010-11-07	2012-05-10	Targegen, Inc.	Compositions and methods for treating myelofibrosis
JP5957003B2 (ja)	2010-11-10	2016-07-27	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	変異体選択的ｅｇｆｒ阻害剤およびその使用
AU2011329642B2 (en)	2010-11-19	2016-08-11	Gilead Sciences, Inc.	Therapeutic compositions comprising rilpivirine HCl and tenofovir disoproxil fumarate
WO2012125993A1 (en)	2011-03-17	2012-09-20	Teva Pharmaceutical Industries Ltd.	Solid state forms of rilpivirine base, and rilipivirine salts
EP2702044B1 (de)	2011-04-25	2017-03-22	Hetero Research Foundation	Verfahren für rilpivirin
CA2844128C (en)	2011-08-30	2020-09-01	Chdi Foundation, Inc.	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2755959B1 (de)	2011-09-16	2018-05-16	Hetero Research Foundation	Rilpivirin-hydrochlorid
EP2770830A4 (de)	2011-10-28	2015-05-27	Celgene Avilomics Res Inc	Verfahren zur behandlung einer bruton-tyrosinkinase-erkrankung oder -störung
WO2013087794A1 (en)	2011-12-14	2013-06-20	Sandoz Ag	Polymorph of rilpivirine hydrochloride and its use as antiviral
EP2604593A1 (de)	2011-12-14	2013-06-19	Sandoz AG	Polymorphe Form von Rilpivirin-Hydrochlorid und ihre antivirale Verwendung
EP2628732A1 (de)	2012-02-20	2013-08-21	Sandoz AG	Neuartige kristalline Form von Rilpivirin-Hydrochlorid
ES2698298T3 (es)	2012-03-15	2019-02-04	Celgene Car Llc	Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
ES2880109T3 (es)	2012-03-15	2021-11-23	Celgene Car Llc	Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
WO2013153162A1 (en)	2012-04-11	2013-10-17	Sandoz Ag	Polymorph of rilpivirine hydrochloride
WO2013153161A2 (en)	2012-04-11	2013-10-17	Sandoz Ag	Novel polymorph of rilpivirine hydrochloride
WO2013179105A1 (en) *	2012-06-01	2013-12-05	Laurus Labs Private Limited	Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
EP2872492B1 (de) *	2012-07-12	2018-01-31	Hetero Research Foundation	Verfahren zur herstellung von rilpivirin über ein neues zwischenprodukt
WO2014072419A1 (en)	2012-11-08	2014-05-15	Universiteit Antwerpen	Novel anti-hiv compounds
US9126950B2 (en)	2012-12-21	2015-09-08	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
US9561228B2 (en)	2013-02-08	2017-02-07	Celgene Avilomics Research, Inc.	ERK inhibitors and uses thereof
US9914709B2 (en)	2013-06-21	2018-03-13	Yale University	Compositions and methods of treating HIV-1 infections using same
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
WO2016011316A1 (en) *	2014-07-17	2016-01-21	Chdi Foundation, Inc.	Methods and compositions for treating hiv-related disorders
WO2016025561A1 (en)	2014-08-13	2016-02-18	Celgene Avilomics Research, Inc.	Forms and compositions of an erk inhibitor
EA201790495A1 (ru)	2014-09-26	2017-09-29	Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед	Фармацевтические композиции длительного действия
CZ201532A3 (cs)	2015-01-21	2015-02-25	Zentiva, K.S.	Způsob výroby vysoce čistého Rilpivirinu a jeho solí
CN104926829A (zh) *	2015-06-08	2015-09-23	山东大学	一种噻吩并嘧啶类衍生物及其制备方法和应用
AU2016287500B2 (en)	2015-06-30	2019-05-02	Gilead Sciences, Inc.	Pharmaceutical formulations comprising tenofovir and emtricitabine
CZ2015579A3 (cs)	2015-08-27	2017-03-08	Zentiva, K.S.	Krystalická forma A Rilpivirin Adipátu a způsob její přípravy
CN106187916B (zh) *	2016-07-04	2018-08-21	宜昌人福药业有限责任公司	一种有效去除利匹韦林异构体的方法
ES2970870T3 (es)	2016-10-24	2024-05-31	Janssen Sciences Ireland Unlimited Co	Composiciones dispersables
CN106749203B (zh) *	2016-11-28	2020-04-10	洛阳聚慧医药科技有限公司	一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
CN106588696B (zh) *	2016-12-08	2018-12-25	西北师范大学	一种反式α,β-不饱和腈类化合物的制备方法
CN106905244B (zh) *	2017-02-27	2019-08-16	武汉工程大学	二芳基嘧啶-二酮酸类杂合型hiv-1抑制剂及其制备方法
JP7287906B2 (ja)	2017-06-30	2023-06-06	ヴィーブヘルスケアカンパニー	組み合わせ並びにその使用及びそれによる治療
TWI827677B (zh)	2018-09-18	2024-01-01	美商尼坎醫療公司	作為src同源-2磷酸酶抑制劑之稠合三環衍生物
CN109293581B (zh) *	2018-09-21	2020-03-27	宜昌人福药业有限责任公司	一种制备盐酸利匹韦林异构体z和杂质x的方法及杂质x作为杀虫剂在农业中的应用
WO2020084142A1 (en)	2018-10-25	2020-04-30	Minakem	Process for the preparation of rilpivirine
CA3144534A1 (en) *	2019-07-03	2021-01-07	Janssen Sciences Ireland Unlimited Company	Methods of treating hiv in pediatric patients with rilpivirine
CN110526873B (zh) *	2019-08-15	2022-09-16	复旦大学	氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
EP4065121A4 (de)	2019-11-29	2023-11-29	Aptorum Therapeutics Limited	Zusammensetzung mit rilpivirin und ihre verwendung zur behandlung von tumoren oder krebs
CN111004215B (zh) *	2019-12-22	2022-08-09	华北理工大学	2,4-取代嘧啶类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN111217833B (zh) *	2020-02-21	2021-03-16	山东大学	噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
US20230310427A1 (en) *	2020-06-30	2023-10-05	University Of South Australia	New therapeutic use of rilpivirine
CN112028836B (zh) *	2020-09-09	2021-12-07	山东大学	一种含有六元氮杂环的二芳基嘧啶类衍生物及其制备方法与应用
CN112010810B (zh) *	2020-09-09	2024-01-30	瑞阳制药股份有限公司	一锅法制备高纯度利匹韦林中间体的方法
WO2022079739A1 (en)	2020-10-14	2022-04-21	Cipla Limited	Fixed dose compositions of cabotegravir and rilpivirine
TW202233192A (zh)	2020-11-17	2022-09-01	愛爾蘭商健生科學愛爾蘭無限公司	Hiv感染之治療或預防
CN112546969B (zh) *	2020-12-07	2022-12-23	安徽贝克制药股份有限公司	催化加氢连续生产装置和利托那韦中间体的制备方法
CN112778214A (zh) *	2021-01-13	2021-05-11	安徽贝克联合制药有限公司	用于合成利匹韦林的中间体、其合成方法和利匹韦林的合成方法
CN113105394A (zh) *	2021-03-08	2021-07-13	复旦大学	一种含芳杂环结构的联苯二芳基嘧啶类衍生物及其制备方法和应用
CN113461666A (zh) *	2021-05-06	2021-10-01	复旦大学	含芳杂环结构的联苯二芳基甲基嘧啶衍生物及其制备方法
CN113845515A (zh) *	2021-09-03	2021-12-28	复旦大学	一种含芳杂环结构的二甲基联苯二芳基嘧啶类衍生物及其制备方法和应用
KR20240095514A (ko)	2021-11-17	2024-06-25	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	용해도 평가
TW202408580A (zh)	2022-04-22	2024-03-01	愛爾蘭商健生科學愛爾蘭無限公司	冷凍乾燥組成物(二)
CN119403543A (zh)	2022-04-22	2025-02-07	爱尔兰詹森科学公司	液体组合物
WO2023222754A1 (en)	2022-05-17	2023-11-23	Janssen Sciences Ireland Unlimited Company	Rilpivirine for use in the treatment or prevention of hiv infection
TW202408527A (zh)	2022-05-17	2024-03-01	愛爾蘭商健生科學愛爾蘭無限公司	治療或預防hiv感染(二)
CN115490642B (zh) *	2022-09-21	2024-11-15	山东大学	一种含醚键的二芳基嘧啶类化合物及其制备方法与应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3459731A (en)	1966-12-16	1969-08-05	Corn Products Co	Cyclodextrin polyethers and their production
US3953398A (en) *	1970-07-20	1976-04-27	The Goodyear Tire & Rubber Company	Age resistant polymeric compositions
JPS63159316A (ja) *	1977-11-28	1988-07-02	アルキユサル　インコーポレーテツド　ピーテイワイ　リミテツド	中性銅結合体を含む抗炎症組成物
JPS5490121A (en) *	1977-11-28	1979-07-17	Boettcher Barry	Neutral copper bonded body and antiinflaming agent
JPS5879920A (ja) *	1981-11-09	1983-05-13	Kanegafuchi Chem Ind Co Ltd	血小板凝集阻害剤
GB9012592D0 (en)	1990-06-06	1990-07-25	Smithkline Beecham Intercredit	Compounds
US5318780A (en) *	1991-10-30	1994-06-07	Mediventures Inc.	Medical uses of in situ formed gels
US5691364A (en)	1995-03-10	1997-11-25	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) *	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
CN1198655C (zh)	1995-11-23	2005-04-27	詹森药业有限公司	通过熔体挤出法制备的环糊精固体混合物
TW429256B (en)	1995-12-27	2001-04-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
GB9705361D0 (en)	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
JP3990808B2 (ja) *	1998-03-26	2007-10-17	Ｔｄｋ株式会社	非水電解質電池用電極の製造方法
DE69943247D1 (de) *	1998-03-27	2011-04-14	Janssen Pharmaceutica Nv	HIV hemmende Pyrimidin Derivate
EE04850B1 (et)	1998-03-27	2007-06-15	Janssen Pharmaceutica N.V.	Pürimidiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutamiseks HIV nakku
EP0945447A1 (de) *	1998-03-27	1999-09-29	Janssen Pharmaceutica N.V.	Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen
JP2000035628A (ja) *	1998-07-16	2000-02-02	Konica Corp	ハロゲン化銀写真感光材料
WO2000012485A1 (en) *	1998-08-29	2000-03-09	Astrazeneca Ab	Pyrimidine compounds
KR100658489B1 (ko) *	1998-11-10	2006-12-18	얀센 파마슈티카 엔.브이.	Ｈｉｖ 복제를 억제하는 피리미딘
DK1159279T3 (da)	1999-03-09	2003-02-17	Upjohn Co	4-Oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamider som antivirale midler
PT1169038E (pt)	1999-04-15	2012-10-26	Bristol Myers Squibb Co	Inibidores cíclicos da proteína tirosina cinase
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
AU775360B2 (en) *	1999-09-24	2004-07-29	Janssen Pharmaceutica N.V.	Antiviral compositions
DE19945982A1 (de)	1999-09-24	2001-03-29	Knoll Ag	Geschwindigkeitsbestimmte Partikel
AU2001237041B9 (en) *	2000-02-17	2005-07-28	Amgen Inc.	Kinase inhibitors
GB0004888D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004887D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
ES2542326T3 (es)	2000-05-08	2015-08-04	Janssen Pharmaceutica Nv	Inhibidores de la replicación del VIH
DK1282607T3 (en)	2000-05-08	2016-02-01	Janssen Pharmaceutica Nv	Prodrugs of HIV replication inhibiting pyrimidines
US6596729B2 (en)	2000-07-20	2003-07-22	Bristol-Myers Squibb Company	Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
JP2004525914A (ja)	2001-03-02	2004-08-26	スミスクラインビーチャムコーポレーション	逆転写酵素阻害剤としてのベンゾフェノン類
WO2002079197A1 (en) *	2001-03-29	2002-10-10	Vertex Pharmaceuticals Incorporated	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) *	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
WO2003020210A2 (en) *	2001-08-29	2003-03-13	Umd, Inc.	Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
TWI329105B (en) *	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
EA008244B1 (ru) *	2002-05-03	2007-04-27	Янссен Фармацевтика Н.В.	Полимерные микроэмульсии
HRP20050104B1 (hr)	2002-08-09	2014-02-14	Janssen Pharmaceutica N.V.	Postupci za pripremu 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
AU2002350719A1 (en) *	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CN102151270A (zh) *	2003-02-07	2011-08-17	詹森药业有限公司	预防hiv感染的嘧啶衍生物
WO2011103559A1 (en) *	2010-02-22	2011-08-25	Nektar Therapeutics	Oligomer modified diaromatic substituted compounds

2002
- 2002-07-16 JO JOP/2002/0074A patent/JO3429B1/ar active
- 2002-08-09 KR KR1020047000372A patent/KR100817453B1/ko not_active Expired - Lifetime
- 2002-08-09 IL IL16032802A patent/IL160328A0/xx active IP Right Grant
- 2002-08-09 CN CNB028159209A patent/CN100509801C/zh not_active Expired - Lifetime
- 2002-08-09 HU HU1900370A patent/HU231274B1/hu active Protection Beyond IP Right Term
- 2002-08-09 ES ES02764839T patent/ES2368996T3/es not_active Expired - Lifetime
- 2002-08-09 EP EP10178189.6A patent/EP2298761B1/de not_active Expired - Lifetime
- 2002-08-09 EP EP02764839A patent/EP1419152B1/de not_active Expired - Lifetime
- 2002-08-09 DK DK20165399.5T patent/DK3808743T3/da active
- 2002-08-09 AP APAP/P/2004/002993A patent/AP1610A/en active
- 2002-08-09 KR KR1020077022611A patent/KR100969273B1/ko not_active Expired - Lifetime
- 2002-08-09 AU AU2002329238A patent/AU2002329238C1/en active Active
- 2002-08-09 HR HRP20040096AA patent/HRP20040096B1/hr not_active IP Right Cessation
- 2002-08-09 CN CN200910145401.5A patent/CN101816658B/zh not_active Expired - Lifetime
- 2002-08-09 MX MXPA04001401A patent/MXPA04001401A/es active IP Right Grant
- 2002-08-09 HR HRP20120265A patent/HRP20120265B1/hr not_active IP Right Cessation
- 2002-08-09 MY MYPI20071005A patent/MY189572A/en unknown
- 2002-08-09 SI SI200231101T patent/SI3808743T1/sl unknown
- 2002-08-09 HR HRP20192051AA patent/HRP20192051B1/hr not_active IP Right Cessation
- 2002-08-09 BR BR122015023612A patent/BR122015023612B8/pt not_active IP Right Cessation
- 2002-08-09 BR BRPI0211909-9 patent/BRPI0211909B8/pt active IP Right Grant
- 2002-08-09 WO PCT/EP2002/008953 patent/WO2003016306A1/en not_active Ceased
- 2002-08-09 BR BR122015032641-9A patent/BR122015032641B1/pt not_active IP Right Cessation
- 2002-08-09 ES ES10178189T patent/ES2799408T3/es not_active Expired - Lifetime
- 2002-08-09 EP EP20165399.5A patent/EP3808743B1/de not_active Expired - Lifetime
- 2002-08-09 JP JP2003521229A patent/JP2005507380A/ja not_active Withdrawn
- 2002-08-09 ES ES20165399T patent/ES2923581T3/es not_active Expired - Lifetime
- 2002-08-09 PL PL368270A patent/PL216398B1/pl unknown
- 2002-08-09 NZ NZ530951A patent/NZ530951A/en not_active IP Right Cessation
- 2002-08-09 CA CA002452217A patent/CA2452217C/en not_active Expired - Lifetime
- 2002-08-09 PT PT02764839T patent/PT1419152E/pt unknown
- 2002-08-09 LT LTEP20165399.5T patent/LT3808743T/lt unknown
- 2002-08-09 US US10/485,636 patent/US7125879B2/en not_active Expired - Lifetime
- 2002-08-09 SI SI200230963T patent/SI1419152T1/sl unknown
- 2002-08-09 DK DK02764839.3T patent/DK1419152T3/da active
- 2002-08-09 PL PL402388A patent/PL402388A1/pl unknown
- 2002-08-09 EA EA200400304A patent/EA006656B1/ru active IP Right Maintenance
- 2002-08-09 AT AT02764839T patent/ATE517891T1/de active
- 2002-08-09 HU HU0401346A patent/HU230192B1/hu active Protection Beyond IP Right Term
- 2002-08-09 OA OA1200400047A patent/OA12652A/en unknown
- 2002-08-10 EG EG2002080892A patent/EG24684A/xx active
- 2002-08-12 AR ARP020103034A patent/AR036387A1/es active IP Right Grant
- 2002-08-12 PA PA20028552901A patent/PA8552901A1/es unknown
- 2002-09-08 UA UA2004031903A patent/UA78221C2/uk unknown
2004
- 2004-02-11 IL IL160328A patent/IL160328A/en active Protection Beyond IP Right Term
- 2004-02-12 ZA ZA2004/01159A patent/ZA200401159B/en unknown
- 2004-02-12 NO NO20040633A patent/NO327639B1/no not_active IP Right Cessation
2006
- 2006-06-26 US US11/474,855 patent/US8080551B2/en not_active Expired - Fee Related
2008
- 2008-09-02 NO NO20083770A patent/NO337142B1/no not_active IP Right Cessation
2009
- 2009-11-12 JP JP2009259107A patent/JP5247661B2/ja not_active Expired - Lifetime
2011
- 2011-06-16 JP JP2011134088A patent/JP4838396B2/ja not_active Expired - Lifetime
- 2011-06-17 JP JP2011135468A patent/JP5539927B2/ja not_active Expired - Lifetime
- 2011-09-30 US US13/249,796 patent/US20120076835A1/en not_active Abandoned
- 2011-10-26 CY CY20111101014T patent/CY1112331T1/el unknown
2012
- 2012-05-04 LT LTPA2012008C patent/LTC1419152I2/lt unknown
- 2012-05-08 BE BE2012C020C patent/BE2012C020I2/nl unknown
- 2012-05-16 LU LU92001C patent/LU92001I2/fr unknown
- 2012-05-18 CY CY2012012C patent/CY2012012I2/el unknown
- 2012-05-22 FR FR12C0035C patent/FR12C0035I2/fr active Active
- 2012-05-23 NO NO2012010C patent/NO2012010I2/no unknown
- 2012-05-24 LU LU92008C patent/LU92008I2/fr unknown
- 2012-05-24 BE BE2012C022C patent/BE2012C022I2/nl unknown
- 2012-05-25 DE DE201212000038 patent/DE122012000038I1/de active Pending
- 2012-05-25 CY CY2012013C patent/CY2012013I1/el unknown
- 2012-05-25 FR FR12C0036C patent/FR12C0036I2/fr active Active
2014
- 2014-08-05 US US14/451,761 patent/US9580392B2/en not_active Expired - Fee Related
2015
- 2015-10-20 HU HUS1500051C patent/HUS1500051I1/hu unknown
2016
- 2016-02-03 HU HUS1500055C patent/HUS1500055I1/hu unknown
2017
- 2017-01-16 US US15/406,918 patent/US20170121292A1/en not_active Abandoned
- 2017-07-20 US US15/655,570 patent/US9981919B2/en not_active Expired - Lifetime
2018
- 2018-04-26 US US15/963,352 patent/US10370340B2/en not_active Expired - Fee Related
2019
- 2019-07-02 US US16/460,898 patent/US10611732B2/en not_active Expired - Fee Related
2022
- 2022-07-27 FR FR22C1036C patent/FR22C1036I1/fr active Active
- 2022-07-28 BE BE2022C531C patent/BE2022C531I2/nl unknown
- 2022-08-01 CY CY2022024C patent/CY2022024I1/el unknown
- 2022-08-02 LT LTPA2022515C patent/LTC3808743I2/lt unknown
- 2022-08-02 HU HUS2200038C patent/HUS2200038I1/hu unknown

Also Published As

Publication number	Publication date
DK1419152T3 (da)	2011-10-24
NO2012010I1 (no)	2012-06-18
CY2012012I1 (el)	2015-08-05
EA200400304A1 (ru)	2004-08-26
PL216398B1 (pl)	2014-03-31
CN1541215A (zh)	2004-10-27
OA12652A (en)	2006-06-15
FR12C0035I1 (de)	2012-06-22
FR12C0036I1 (de)	2012-06-29
ES2799408T3 (es)	2020-12-17
WO2003016306A1 (en)	2003-02-27
AU2002329238C1 (en)	2008-08-28
US20170320835A1 (en)	2017-11-09
US20170121292A1 (en)	2017-05-04
BE2012C022I2 (de)	2022-01-12
BR0211909A (pt)	2004-08-24
US9580392B2 (en)	2017-02-28
CY2022024I2 (el)	2023-01-05
CA2452217C (en)	2009-06-16
AP2004002993A0 (en)	2004-03-31
ES2368996T3 (es)	2011-11-24
NO20083770L (no)	2004-03-12
LTC3808743I2 (de)	2023-04-25
HUP0401346A3 (en)	2009-03-02
JP5539927B2 (ja)	2014-07-02
BR122015032641B1 (pt)	2022-03-03
HUP0401346A2 (hu)	2004-12-28
LTPA2022515I1 (de)	2022-08-25
LU92001I2 (fr)	2012-07-16
EP2298761A1 (de)	2011-03-23
CY2012012I2 (el)	2015-08-05
CN101816658B (zh)	2014-08-27
US10611732B2 (en)	2020-04-07
CY2012013I2 (el)	2015-08-05
SI1419152T1 (sl)	2011-11-30
KR20040023645A (ko)	2004-03-18
KR100969273B1 (ko)	2010-08-20
CY2022024I1 (el)	2023-01-05
UA78221C2 (uk)	2007-03-15
FR12C0035I2 (fr)	2016-02-12
KR20070101409A (ko)	2007-10-16
US20040198739A1 (en)	2004-10-07
HK1070066A1 (en)	2005-06-10
EP3808743B1 (de)	2022-07-20
US8080551B2 (en)	2011-12-20
PT1419152E (pt)	2011-10-11
JP2005507380A (ja)	2005-03-17
NO337142B1 (no)	2016-02-01
CN101816658A (zh)	2010-09-01
HRP20120265B1 (hr)	2019-11-29
HRP20040096B1 (hr)	2013-06-30
DK3808743T3 (da)	2022-08-01
US10370340B2 (en)	2019-08-06
CA2452217A1 (en)	2003-02-27
JP2010077140A (ja)	2010-04-08
AU2002329238B2 (en)	2008-01-24
EA006656B1 (ru)	2006-02-24
JP2011225589A (ja)	2011-11-10
ZA200401159B (en)	2005-07-27
KR100817453B1 (ko)	2008-03-27
FR22C1036I1 (fr)	2022-09-09
CY1112331T1 (el)	2015-08-05
US20180244632A1 (en)	2018-08-30
NO2012010I2 (no)	2013-09-02
LT3808743T (lt)	2022-08-10
BR122015023612B1 (pt)	2021-01-19
AR036387A1 (es)	2004-09-08
ATE517891T1 (de)	2011-08-15
HK1145449A1 (en)	2011-04-21
PA8552901A1 (es)	2003-02-28
US7125879B2 (en)	2006-10-24
EP1419152A1 (de)	2004-05-19
LTC1419152I2 (lt)	2025-05-12
EP3808743A1 (de)	2021-04-21
LU92008I2 (fr)	2012-07-24
US20120076835A1 (en)	2012-03-29
HRP20040096A2 (en)	2004-06-30
CY2012013I1 (el)	2015-08-05
HUS1500051I1 (hu)	2018-05-28
BRPI0211909B8 (pt)	2021-05-25
NZ530951A (en)	2005-10-28
ES2923581T3 (es)	2022-09-28
EG24684A (en)	2010-05-05
SI3808743T1 (sl)	2022-09-30
MY189572A (en)	2022-02-17
US20190322628A1 (en)	2019-10-24
NO20040633L (no)	2004-03-12
JO3429B1 (ar)	2019-10-20
EP1419152B1 (de)	2011-07-27
CN100509801C (zh)	2009-07-08
LTPA2012008I1 (lt)	2012-06-25
FR12C0036I2 (fr)	2016-05-06
BRPI0211909B1 (pt)	2018-05-29
HUS2200038I1 (hu)	2022-08-28
BE2022C531I2 (de)	2022-08-09
HRP20192051B1 (hr)	2022-05-27
EP2298761B1 (de)	2020-03-25
HRP20120265A2 (hr)	2012-05-31
MXPA04001401A (es)	2004-05-27
PL368270A1 (en)	2005-03-21
US20140343006A1 (en)	2014-11-20
US20060252764A1 (en)	2006-11-09
JP4838396B2 (ja)	2011-12-14
AP1610A (en)	2006-05-08
HU231274B1 (hu)	2022-07-28
JP2011236221A (ja)	2011-11-24
BE2012C020I2 (de)	2021-07-19
BR122015023612B8 (pt)	2021-05-25
US9981919B2 (en)	2018-05-29
JP5247661B2 (ja)	2013-07-24
HRP20192051A2 (hr)	2020-03-06
HU230192B1 (hu)	2015-09-28
PL402388A1 (pl)	2013-04-02
HUS1500055I1 (hu)	2016-03-29
IL160328A0 (en)	2004-07-25
IL160328A (en)	2011-01-31
NO327639B1 (no)	2009-09-07

Publication	Publication Date	Title
DE122012000038I1 (de)	2012-09-20	HIV hemmende pyrimidine derivaten.
ATE309245T1 (de)	2005-11-15	5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3- d)pyrimidin-derivate
NO20040540L (no)	2004-02-05	4-amino-6-fenylpyrrolo[2,3-D]pyrimidinderivater.
DE60130463D1 (de)	2007-10-25	Pyrimidin-derivate
ATE370120T1 (de)	2007-09-15	Substituierte 2-pyridin-cyclohexan-1,4- diaminderivate
NO20042742L (no)	2004-08-24	Pyrimidinforbindelser
NO20040654L (no)	2004-05-14	Gassmikrosfaere-liposomkompositter.
NO20040387L (no)	2004-03-24	Nedihullsfrigjoringskopling.
ES1050481Y (es)	2002-11-16	Pieza de construccion.
BR0103827B1 (pt)	2012-08-21	cola - pds.
ES1050491Y (es)	2002-08-01	Chupete infantil.
BR8101236Y1 (pt)	2011-12-27	desensiladeira.
ES1057516Y (es)	2005-04-16	Pieza rodapie mejorada.
ES1050980Y (es)	2003-09-16	Portalamparas.
ES1048140Y (es)	2001-11-01	Calcetin-zapato.
ES1048703Y (es)	2002-02-01	Conversor.
ES1049298Y (es)	2002-03-16	Embalaje-expositor.
ES1053113Y (es)	2003-07-01	Tenedor-expulsor.
ITSA20010007A0 (it)	2001-03-15	Recordbio.
ITPC20010029A1 (it)	2003-03-26	Dimagrimento - anticellulite - rassodamento - rimodellamento.
ITRM20010044U1 (it)	2001-06-11	Bloccaprosciutto.
ITBN20010003U1 (it)	2001-04-26	Distanziatore -dcz2- car-zaottini.
ITSA20010007U1 (it)	2003-01-13	Termo-materasso.
ITBN20010002U1 (it)	2001-04-26	Distanziatore -dcz1- car-zaottini.
ITBN20010001U1 (it)	2001-04-26	Distanziatore -dc z3- car-zaottini.